DSM-FIRMENICH

dsm-firmenich and OMG Pharma form strategic collaboration to advance first-of-a-kind CBD-based drugs for insomnia

3 April 2024 – Kaiseraugst, Switzerland; Heerlen, Netherlands – dsm-firmenich, has announced a new strategic collaboration with Oz Medicann Group (OMG) Pharma – an Australian-based biotech innovator in the cannabinoid medicines domain – to explore the therapeutic potential of cannabidiol (CBD)-based orally dispersible tablets addressing insomnia. Leveraging dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient...

DSM-FIRMENICH TO DEBUT AT CPHI, SHARING ITS VISION FOR PURPOSE-POWERED SOLUTIONS FOR THE PHARMACEUTICAL INDUSTRY

3 October 2023 – Kaiseraugst, Switzerland – Following the merger of two iconic companies – DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care. The company, which has shared sales of more than €12bn and a...